On 9 December, 2019, HBeAg diagnostic kit (Chemiluminescent Microparticle Immunoassay) achieved medical device registration certificate.
This kit is used to quantitatively detect Hepatitis B virus E antigen (HBeAg) in human plasma or serum.
To know about product:
Hepatitis B virus infection has become a common and important public health problem in the world. At present, there are 350 million to 400 million chronic HBV infected persons world-widely, and 2 billion people have been infected with HBV, accounting for about 6% of the global population.Hepatitis B virus E antigen is a marker of viral replication.Studies have shown that HBeAg level has a good predictive value for hepatitis B treatment response during PegIFNα2a treatment.Many experts pay attention to the dynamic changes of HBeAg and HBsAg concentrations during peginterferon therapy, and believe that such changes are the premise of antigen disappearance or serum conversion, which can predict the curative effect.
Patients with significantly decreased concentrations of HBsAg and HBeAg during hepatitis B treatment should be encouraged to continue the treatment in order to achieve better efficacy.